

1 **Neutrophils impose strong selective pressure against PfEMP1 variants implicated in**  
2 **cerebral malaria**

3  
4 Tamir Zelter<sup>1,2</sup>, Jacob Strahilevitz<sup>3</sup>, Karina Simantov<sup>2</sup>, Olga Yajuk<sup>1</sup>, Anja Ramstedt  
5 Jensen<sup>4</sup>, Ron Dzikowski<sup>2\*</sup> and Zvi Granot<sup>1\*</sup>

6  
7 <sup>1</sup>. Department of Developmental Biology and Cancer Research, Institute for Medical  
8 Research Israel Canada, Hebrew University Medical School, 91120 Jerusalem, Israel.

9 <sup>2</sup>. Department of Microbiology and Molecular Genetics, Institute for Medical Research  
10 Israel-Canada and Kuvim Center for the Study of Infectious and Tropical Diseases,  
11 Hebrew University Hadassah Medical School, Jerusalem 91120, Israel

12 <sup>3</sup>. Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew  
13 University Medical Center, Jerusalem, Israel.

14 <sup>4</sup>. Department of Immunology and Microbiology, University of Copenhagen, Copenhagen,  
15 Denmark

16  
17  
18  
19 \* Corresponding authors – Zvi Granot, Department of Developmental Biology and Cancer  
20 Research, Institute for Medical Research Israel Canada, Hebrew University Medical  
21 School, 91120, Jerusalem, Israel. [zvikag@ekmd.huji.ac.il](mailto:zvikag@ekmd.huji.ac.il). Ron Dzikowski, Department  
22 of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada  
23 and Kuvim Center for the Study of Infectious and Tropical Diseases, Hebrew University  
24 Hadassah Medical School, Jerusalem 91120, Israel. [rond@ekmd.huji.ac.il](mailto:rond@ekmd.huji.ac.il)

25 **Abstract**

26 *Plasmodium falciparum*, the deadliest form of human malaria, remains one of the  
27 major threats to human health in endemic regions. Its virulence is attributed to its ability to  
28 modify infected red blood cells (iRBC) to adhere to endothelial receptors by placing  
29 variable antigens known as PfEMP1 on the surface of the red cell. PfEMP1 expression on  
30 the red cell surface determines the cytoadhesive properties of the iRBCs and is implicated  
31 in severe manifestations of malaria. To evade antibody mediated responses the parasite  
32 undergoes continuous switches of expression between different PfEMP1 variants. Recently  
33 it became clear that in addition to antibody mediated responses, PfEMP1 triggers an innate  
34 immune response, however, the role of neutrophils, the most abundant white blood cells in  
35 the human circulation, in malaria remains elusive. Here we show that neutrophils recognize  
36 and kill blood stages of several *P. falciparum* isolates, and we identify neutrophil ICAM-  
37 1 and specific PfEMP1s implicated in cerebral malaria as the key molecules involved in  
38 this killing. Our data provide mechanistic insight into the interactions between neutrophils  
39 and iRBCs and demonstrate the important influence of PfEMP1 on the selective innate  
40 response to cerebral malaria.

41

42 **Keywords**

43 Malaria, Plasmodium falciparum, Neutrophils, PfEMP1, ICAM1, cerebral malaria

44 **Significance Statement**

45 The role played by neutrophils in malaria infection is only poorly understood. In, this  
46 study we show that neutrophils recognize and kill red blood cells infected by *P. falciparum*,  
47 the parasite causing the most virulent form of malaria. Our findings demonstrate that  
48 neutrophils may act as the first line of defense against severe disease, by recognizing  
49 specific PfEMP1 molecules on RBCs via their ICAM-1. This ligand-receptor interaction  
50 leads to efficient killing of RBCs infected by *falciparum*-parasites associated with cerebral  
51 malaria (CM).

52

53 **Conflict of interest**

54 The Authors confirm that they have no conflict of interests

55

56

## 57 **Introduction**

58 *Plasmodium falciparum* is the protozoan parasite responsible for the deadliest form of  
59 human malaria, which remains one of the major infectious diseases influencing mankind.  
60 This parasite infects hundreds of millions of people worldwide, resulting in approximately  
61 half a million deaths per year, primarily of young children (1). *P. falciparum* replicates  
62 within circulating red blood cells of infected individuals, and its virulence is attributed to  
63 immune evasion through its ability to modify the erythrocyte surface.

64 *Plasmodium*, like other protozoan and bacterial pathogens, has the ability to vary  
65 infected host cell surface protein expression, and as a result, alter the profile of antigens  
66 that are exposed to the host immune system. The process of antigenic variation involves  
67 the variable expression of genes that encode immuno-dominant surface antigens. These  
68 surface antigens frequently play a role in the virulence of the disease, thus linking antigenic  
69 variation to pathogenicity (2). Immune evasion of *P. falciparum* is achieved in two known  
70 ways: 1. modified infected erythrocytes adhere to different endothelial receptors found on  
71 blood vessel walls, thus avoiding the peripheral circulation and removal by the spleen; 2.  
72 they undergo antigenic variation to prevent host immune recognition of surface antigens.  
73 The major antigenic ligands responsible for adherence are members of the *P. falciparum*  
74 **Erythrocyte Membrane Protein-1 (PfEMP1)** family (3), antigenically variable proteins that  
75 are placed on the surface of infected red blood cells (iRBC) and bind to different host  
76 vascular adhesion molecules such as CD36, ICAM-1, CSA and EPCR (4-7) . Sequestration  
77 of iRBCs in different organs contributes to life threatening manifestations of the disease  
78 such as cerebral and pregnancy-associated malaria (8). Therefore, PfEMP1 is considered  
79 the main virulence factor of malaria caused by *P. falciparum* (9). The presence of PfEMP1

80 on the red cell surface stimulates the antibody response of the host, often successfully  
81 clearing the majority of iRBCs from the circulation. However, small sub-populations of  
82 parasites switch expression to an alternative PfEMP1 on the surface of iRBCs, thus  
83 avoiding the antibody response and re-establishing the infection (10). This process is  
84 referred to as antigenic variation and is responsible for the persistent nature of the disease  
85 as well as the waves of parasitemia frequently observed in *P. falciparum* infections (11).

86 Over the past decades, significant efforts were invested in understanding immune  
87 responses in the context of malaria. In this regard, there have been major advances in our  
88 understanding of adaptive immune responses to malaria whereas the role of innate  
89 immunity received much less attention. Still, components of innate immunity, including  
90 NK cells, macrophages and monocytes were shown to play a role in protecting the host  
91 against malaria infection (12, 13). It is somewhat surprising that the role of neutrophils,  
92 which are the most abundant of all white blood cells in the human circulation and represent  
93 the first line of defense against microbial infections, is understudied in the context of  
94 malaria. Neutrophils are phagocytic cells equipped with a wide range of receptors and a  
95 variety of antimicrobial weapons. On top of eliminating microbes via phagocytosis, they  
96 can also de-granulate and deploy neutrophil extracellular traps (NETs) (14, 15). These  
97 features make neutrophils highly potent scavengers for a variety of pathogens, which  
98 suggests that they may play a role in the immune response against malaria infections.  
99 Indeed, several studies have shown that TNF $\alpha$  stimulated neutrophils have the capacity to  
100 phagocytose parasites *in vitro* (16). In addition, hemozoin containing neutrophils have been  
101 previously reported in clinical isolates (17) and neutrophils were claimed to have the

102 capacity to limit the progression of malaria infection (18-20). However, the mechanism by  
103 which neutrophils recognize and kill intra erythrocytic blood stage parasites is unknown.

104 Neutrophils were shown to be able to identify parasite derived alterations on the RBC  
105 membrane. For example, neutrophils recognize RBCs alterations caused by trypanosome-  
106 secreted microvesicles and eliminate these RBCs from the circulation (21). Given the  
107 extensive variable modifications induced by *P. falciparum* parasites on the surface of the  
108 iRBC and its association with different adhesion phenotypes that determine some of the  
109 most severe manifestations of malaria (9), we were interested to study the possible  
110 molecular interaction between neutrophils and iRBCs.

111 Here we demonstrate that neutrophils form physical contact with iRBCs and kill intra-  
112 erythrocytic stages of malaria parasites. We further show that the interaction between  
113 neutrophils and iRBCs is mediated by PfEMP1 on the iRBC surface and neutrophil  
114 expressed ICAM-1. In addition, we demonstrate that neutrophils impose strong selective  
115 pressure on parasite subpopulations expressing PfEMP1 variants, which were implicated  
116 in cerebral malaria. Taken together, these data provide novel molecular insights into the  
117 mechanisms by which neutrophils contribute to the innate immune response during malaria  
118 infection as a selective factor that may influence antigenic expression and protect against  
119 severe cerebral manifestations.

## 120 **Materials and Methods**

### 121 *Parasites and Cell Cultures*

122 All parasites used were derivatives of the NF54, R7Dd2, DC-J and a field isolate from  
123 Sierra Leone (SL). Parasite lines were cultivated at 5% (v/v) hematocrit in RPMI medium  
124 1640, 0.5% (v/v) Albumax II (Invitrogen), 0.25% sodium bicarbonate and 0.1 mg/mL  
125 gentamicin. Parasites were incubated at 37°C in an atmosphere of 5% (v/v) oxygen, 5%  
126 (v/v) carbon dioxide, and 90% (v/v) nitrogen. NF54 parasite line expressing the PFD1235w  
127 *var* gene was selected using antibodies against DBL $\beta$ \_D4 domains of specific ICAM-1  
128 binding PfEMP1s as described (4).

129 The human myeloid leukemia cell line PLB-985 (a generous gift from Dr. Borko  
130 Amulic) was cultured in RPMI-1640 medium supplemented with 10% FCS, 2 mM L-  
131 glutamine, 100 units/ml penicillin and 100  $\mu$ g/ml streptomycin at 37°C in a humidified  
132 atmosphere of 5% CO<sub>2</sub> in air. Cell cultures were passaged 2-3 times a week to maintain a  
133 cell density of  $2 \times 10^5$ - $10^6$  cells/ml. ICAM-1kd PLB985 cells were generated by lentiviral  
134 transduction with ICAM-1 specific shRNAs from Sigma (TRCN0000372478). EPCRkd  
135 PLB985 cells were generated by lentiviral transduction with EPCR specific shRNAs from  
136 Sigma (TRCN0000300553). Control cells were transduced an empty vector (pLKO). For  
137 granulocytic differentiation, exponentially growing PLB-985 cells at a starting density of  
138  $2 \times 10^5$ /ml were cultured in RPMI-1640 medium supplemented with 0.5% DMF and 0.5%  
139 FCS for 6 days. The medium was changed once on day 3 during the differentiation period.

140

### 141 *Parasite Transfections and Selections*

142 For neutrophil-iRBC interaction assays the DC-J and NF54 parasite lines (22) were  
143 transfected with pH<sub>gfp</sub>TIDH plasmids that constitutively express GFP fused to an unrelated  
144 exogenous protein (tet repressor). This construct was made by replacing the *luciferase*  
145 sequence in pHLIRH expression vector (23) with the *tet-gfp* fusion using *HindIII* and  
146 *BamHI*. Parasites were transfected as previously described (24, 25). For luciferase killing  
147 assays, the DC-J parasite line was transfected with pHLI1055Dh plasmid to constitutively  
148 express luciferase (26). Stable transfectants carrying plasmids with hDHFR-selectable  
149 marker were selected with 4 nM WR99210. Selection for PfEMP1-null expression in the  
150 transgenic line DC-J was done using 2 µg/ml blasticidin.

151

#### 152 *Neutrophil Purification*

153 Neutrophils were isolated as previously described (27). In brief, heparinized blood (20  
154 U/ml) collected from healthy donors was mixed with an equal volume of Dextran 500 (3%  
155 in saline) and incubated for 30 minutes at room temperature. The leukocyte-rich  
156 supernatant was layered on top of Histopaque 1077 (Sigma) and centrifuged at 400 × g for  
157 30 minutes. Neutrophils were collected in the pellet fraction and were resuspended in 20  
158 ml 0.2% NaCl for 30 seconds to remove contaminating erythrocytes. Isotonicity was  
159 restored by the addition of 20 ml 1.6% NaCl. Neutrophils were then washed three times in  
160 PBS. Neutrophil purity and viability were determined visually and were consistently  
161 >98%. All blood donors provided written informed consent in accordance with the  
162 Declaration of Helsinki. The medical ethics committee of the Hadassah-Hebrew University  
163 Medical Center approved the used protocol.

164



165 *Late-staged iRBCs Isolation*

166 Parasite cultures were synchronized using Percoll/sorbitol gradient centrifugation as  
167 previously described (22). Briefly, iRBCs were layered on a step gradient of 40%/70%  
168 (v/v) Percoll containing 6% (w/v) sorbitol. The gradients were then centrifuged at 12,000  
169 × g for 20 min at room temperature. Tightly synchronized, late-stage parasites were  
170 recovered from the 40%/70% interphase, washed twice with complete culture media and  
171 counted.

172

173 *Parasite staining for flow cytometry interaction assays*

174 MitoTracker Red CMXRos (ThermoFisher M7512) dye was dissolved in DMSO at a  
175 concentration of 1 mM and stored at -20 °C until use. A 5 μM working solution was  
176 prepared with culture media prior to staining tightly synchronized late stages iRBCs.  
177 Approximately, 10<sup>6</sup> iRBC were resuspended in 100 μl of 5 μM CMXRos and incubated at  
178 37°C for 30 min. iRBCs were washed twice with growth media to remove unbound dye.

179 *Neutrophil-iRBC interaction assay and opsonization*

180 Primary neutrophils or differentiated PLB985 cells were incubated with fluorescent late-  
181 staged iRBC either expressing GFP or stained using MitoTracker as described, at a 10:1  
182 ratio at 37°C for different time periods. Samples were washed, and the extent of  
183 neutrophils-iRBC interaction (% fluorescent neutrophils) was determined using flow  
184 cytometry. Opsonization of iRBCs was performed by culturing iRBCs with AB human  
185 serum (Sigma) for 30 minutes at 37°C. To assess ligands-receptor specificity to this  
186 interaction we performed these assays using anti-Cd11b antibody (Biolegend Cat #  
187 101211, 10 μl/ml) and a non-PfEMP1-blocking anti-ICAM-1 antibody (Biolegend Cat #

188 322702, 10  $\mu$ l/ml) as negative controls. An anti-ICAM-1 monoclonal antibody (15.2) that  
189 blocks the PfEMP1 binding site (ThermoFisher, MA180910, 10  $\mu$ l/ml) was used as  
190 blocking antibody as described (28). All antibodies were incubated with iRBCs for 30  
191 minutes at room temperature in culture media prior to flow cytometry interaction assays.

192

### 193 *Immunofluorescent staining*

194 Immunofluorescent staining was performed as described before (29) with few  
195 modifications. Briefly, following the co-culture of neutrophils and iRBC, samples were  
196 washed and stained with mouse anti-CD66b (BioLegend Cat # 305112, 1:200). Samples  
197 were then washed, cyto-centrifuged and fixed using a fresh fixative solution (4%  
198 paraformaldehyde (EMS) and 0.0075% glutaraldehyde (EMS) in PBS). Fixed samples  
199 were treated with 0.1% Triton-X100 (Sigma) in PBS and blocked using CAS-Block (Life  
200 Technologies Cat # 008120). Cells were then incubated with a rabbit anti-GFP (Invitrogen  
201 Cat # A11122, 1:250), washed and incubated with Alexa Fluor 568 goat anti-Mouse  
202 (Abcam Cat # ab175473, 1:500) and Alexa Fluor 488 goat anti-rabbit (Molecular Probes  
203 Cat #A11034, 1:250) secondary antibodies. Polyclonal IgG antibodies against the ICAM-  
204 1 binding domain (DBL $\beta$ \_D4) of the PFD1235w PfEMP1 were used for surface labeling  
205 as described (48). Samples were washed and mounted in Fluoroshield mounting medium  
206 with DAPI (abcam), covered with cover slips and imaged. Fluorescent images were  
207 obtained using a Plan Apo  $\lambda$  100 $\times$  oil NA = 1.5, WD = 130  $\mu$ m lens on a Nikon Eclipse Ti-  
208 E microscope equipped with a CoolSNAP Myo CCD camera. Images were processed using  
209 the NIS-Elements AR (4.40 version) software.

210

211 *Growth inhibition of parasite co-cultured with neutrophils*

212 Parasite cultures were synchronized as described above and late stages were counted by  
213 flow cytometry. Approximately  $10^6$  parasites were cultured in 100  $\mu$ l uninfected RBCs,  
214 resulting in a parasitemia of  $\sim 1\%$ . Human neutrophils were isolated as described above and  
215  $10^6$  cells were added to the culture every 24 hours for 5 consecutive days. Parasitemia was  
216 evaluated every 24 hours by flow cytometry. For each experiment neutrophils from the  
217 same donor were used for the 5 consecutive days. Growth inhibition assays were repeated  
218 at least three times.

219

220 *Luciferase-based killing assay*

221 Luciferase expressing parasite cultures were synchronized and late staged parasites were  
222 put back into culture as described. After 20 hours uninfected RBCs were lysed using  
223 Streptolysin O (Sigma) activated with 100 mM DTT. Isolated rings were washed three  
224 times and returned to the culture without uninfected RBCs. After 20 hours isolated iRBCs  
225 were collected and plated in 100  $\mu$ l RPMI-1640 with 2% FCS in 96-wells ( $1 \times 10^6$ /well) and  
226  $10^6$  purified neutrophils were added in a 100  $\mu$ l volume. Following 6 hours incubation,  
227 samples were lysed using saponin, centrifuged and the supernatant was discarded. The  
228 pellet was then lysed using 50  $\mu$ l Bright-GLO (Promega E2620) lysis buffer. Luciferase  
229 activity was measured following addition of 50  $\mu$ l Bright-GLO luciferase substrate, using  
230 Tecan F200 microplate luminescence reader. Extent of killing was determined by the ratio  
231 between parasites alone and parasites co-cultured with neutrophils. Killing assays were  
232 repeated at least three times.

233

234 *Evaluation of culture parasitemia*

235 The level of parasitemia was evaluated by flow cytometry. 50 µl samples taken from  
236 the parasite cultures were washed in PBS and incubated 30 min. with 1:10,000 SYBR  
237 Green I DNA stain (Life Technologies). Since neutrophils have DNA as well,  
238 distinguishing neutrophils was done by adding anti-CD11b-APC antibody (Biolegend  
239 301309) 1:400 in parallel to the SYBR Green staining. APC<sup>+</sup> cells were excluded from the  
240 analysis. The fluorescence profiles of infected erythrocytes were measured on CytoFLEX  
241 (Beckman Coulter) and analyzed by the CytExpert software.

242

243 *RNA extraction and cDNA synthesis*

244 RNA was extracted from synchronized parasite cultures at 20–24 h after percoll/sorbitol  
245 gradient centrifugation. RNA was extracted with the TRIZOL LS Reagent® as described  
246 (30) and purified on PureLink column (Invitrogen) according to manufacturer's protocol.  
247 Isolated RNA was then treated with DNase I (TaKaRa) to degrade contaminating gDNA.  
248 cDNA synthesis was performed from 500 ng total RNA with PrimeScript™ RT Reagent  
249 Kit (TaKaRa) as described by the manufacturer.

250

251 *Real-time RT-qPCR*

252 Steady state mRNA levels of the entire *var* gene family was measured by RT-qPCR  
253 reactions using a primer set designated to detect transcripts of all *var* gene in the NF54  
254 genome (31) with few modifications (32). Transcript copy numbers were determined using  
255 the formula  $2^{-\Delta\Delta CT}$  as described in the Applied Biosystems User Bulletin 2 using NF54  
256 gDNA as the calibrator. Specifically, relative copy number was calculated as 2 exponential

257 negative ((Ct target gene in cDNA – Ct reference gene in cDNA)-(Ct target gene in gDNA  
258 – Ct target gene in gDNA)).

259

### 260 *Soluble protein preparation*

261 For soluble receptor expression, 4T1 cells were infected with viral particles prepared  
262 from tet-inducible pLV\_TRE\_RFP vector (kindly provided by Prof. Eli Keshet, The  
263 Hebrew University of Jerusalem) expressing the respective genes, and mRFP-positive cells  
264 were sorted using BD FACSAria III cell sorter. Soluble receptor expression was induced  
265 by adding 1 µg/ml doxycycline (Sigma) to the cells the day before the assay. sICAM-1-Fc  
266 was prepared by amplifying the extracellular ICAM-1 domain from neutrophil cDNA using  
267 Phusion Flash High-Fidelity PCR master mix. The PCR fragment was inserted into the  
268 pLV\_TRE\_mRFP vector. The mutant Fc fragment of human IgG1 that do not bind Fc  
269 receptors, and as such will not trigger antibody-dependent cell-mediated cytotoxicity  
270 (33), was prepared by amplifying the Fc fragment of the CSI-Ig (Fc mut)-IRES-puro  
271 plasmid kindly provided by Prof. Ofer Mandelboim (The Hebrew University of Jerusalem)  
272 using Phusion Flash High-Fidelity PCR master mix. The mutant Fc fragment was inserted  
273 into the pLV\_TRE\_mRFP vector.

274

### 275 *Lentiviral Infection*

276  $2.5 \times 10^6$  293T cells seeded the day before in 10 ml DMEM+10% heat-inactivated FCS were  
277 transfected with 20 µg of the respective lentiviral vectors, 15 µg of pCMV-ΔR8.91 gag-pol  
278 and 5 µg VSV-G (pMD2.G) using the calcium phosphate DNA precipitation method. For  
279 MigR1-luc retroviral vector pCL-Eco was used as gag-pol instead of ΔR8.91. On the

280 following day, the medium was changed and viral supernatant was collected after 24–48 h  
281 and 0.45  $\mu\text{m}$  filtrated. 4T1 cells were incubated in the filtrated viral supernatant in the  
282 presence of 8  $\mu\text{g}/\text{ml}$  polybrene (Sigma) for 24 h. After 5–7 days, mRFP<sup>+</sup> cells were sorted  
283 using BD FACSARIA III cell sorter. Pooled sorted cells were used for the experiments.

284

### 285 *Statistical Analysis*

286 For experiments comparing differences between two groups, we used paired Student's  
287 t tests. Differences were considered significant when  $P < 0.05$ . Data are presented as mean  
288  $\pm$  SEM.

289

### 290 *Human Data:*

291 Informed consent was obtained from all subjects and that the experiments conformed to  
292 the principles set out in the WMA Declaration of Helsinki for research number 0091-17-  
293 HMO

## 294 **Results**

### 295 **Neutrophils interact with *P. falciparum* iRBCs and kill blood stage parasites**

296 To determine whether naive neutrophils spontaneously recognize and eliminate  
297 iRBCs, we first examined the interaction between neutrophils and iRBCs. Neutrophils were  
298 isolated from healthy donors and co-cultured with iRBCs containing late-stage NF54  
299 parasites constitutively expressing GFP (GFP<sup>+</sup>-NF54). Using bright field and fluorescent  
300 microscopy, neutrophils were shown to form physical contact with iRBCs and phagocytose  
301 the parasites spontaneously (**Fig. 1A & B**). Next, we used flow cytometry to assess the  
302 extent of neutrophils' capacity to interact with RBCs infected with GFP<sup>+</sup>-NF54 parasites.  
303 Following 10 minutes of co-incubation and in the absence of human serum, 30-40% of  
304 neutrophils were GFP<sup>+</sup> (**Fig. 1C middle panel & D**); opsonization of iRBCs with human  
305 serum prior to introducing them into the culture further potentiated this response, with  
306 iRBCs bound to about 50-60% of the neutrophils (**Fig. 1C right panel & D**), indicating  
307 that the response of neutrophils to iRBCs *in vivo* might be more effective than under  
308 controlled culture conditions.

309 A key question arising from these observations is whether the interaction between  
310 neutrophils and iRBCs leads to parasite killing by neutrophils. To test this, we performed  
311 a pulse-chase experiment where RBCs infected with late-stage GFP<sup>+</sup> parasites were  
312 incubated with neutrophils and measured changes in the fraction of GFP<sup>+</sup> neutrophils over  
313 time. We show that the fraction of GFP<sup>+</sup> neutrophils either binding or phagocytosing  
314 iRBCs decreased with time (**Fig. 2A**). We repeated this experiment with opsonized iRBCs  
315 and found that although the fraction of iRBCs interacting with neutrophils was larger  
316 following opsonization (**Fig. 1C & D**), the decrease in the fraction of GFP<sup>+</sup> neutrophils by

317 time was similar to that of neutrophils incubated with non-opsonized iRBCs (**Fig. 2A**).  
318 These data suggest that opsonization can significantly increase the fraction of neutrophils  
319 interacting with iRBCs. However, once in contact, opsonized and non-opsonized iRBCs  
320 are cleared at a similar rate.

321 The time dependent decrease in GFP<sup>+</sup> neutrophils could be interpreted as either loss  
322 of interaction between the neutrophils and iRBCs (escape) or as parasite elimination by  
323 neutrophils (**Fig. 2B**). To discern between these two possibilities and confirm that indeed  
324 the interaction between neutrophils and iRBCs leads to parasite killing, we tested whether  
325 co-culturing neutrophils with iRBC limits the increase in parasitemia. To this end, iRBC  
326 were cultured with neutrophils for 6 days. In light of neutrophils' short life span, we  
327 replenished the neutrophils in the culture every 24 hours to maintain continuous selective  
328 pressure. Our data show that a significant difference in parasitemia may be seen as early as  
329 5 days following the initial introduction of neutrophils to the co-culture (**Fig. 2C**). We  
330 repeated this experiment using three different parasite isolates, two culture adapted lines  
331 (NF54 and Dd2) and a recently adapted parasite obtained from a traveler infected in Sierra  
332 Leone (SL). In addition, to the adapted parasite lines, neutrophils were incubated with DC-  
333 J, a transgenic line that, when grown in the presence of blasticidin, ceases to express the  
334 major surface antigen PfEMP1 (22). The iRBC ratio was measured by flow cytometry daily  
335 and showed that incubation with neutrophils significantly reduced the growth rate of the  
336 NF54, Dd2, SL lines, while the growth rate of the DC-J line lacking PfEMP1 expression  
337 was unaffected (**Fig. 2D-E**). We reasoned that neutrophils may recognize parasite-derived  
338 surface modifications on iRBCs, and thus would interact better with late-stage parasites, in  
339 which modification of their red cell surface is nearly completed. To test this, we used flow



340 cytometry to assess how daily neutrophil challenges affect the distribution of different  
341 parasite stages in tightly synchronized parasite culture. Following the completion of one  
342 parasite replication cycle we found that while there were no late-stage parasites in the  
343 control culture on day 4, there was a significant proportion of late-stage parasites remaining  
344 in the culture challenged with neutrophils (**Fig. 2F**). This suggests that the presence of  
345 neutrophils prohibited parasite cell cycle completion in a significant fraction of iRBCs and  
346 possibly reflects the detection of the DNA remains from dead late stage parasites. To  
347 conclusively determine whether neutrophils kill late stage parasites, we co-cultured  
348 luciferase expressing NF54 parasites (NF54-*luc* (34, 35)) with freshly isolated neutrophils.  
349 Our data show that neutrophils are able to kill late stage luciferase expressing parasites  
350 within 6 hours (**Fig. S1**).

351       Although neutrophils are equipped with a wide array of cytotoxic molecules, most of  
352 these molecules are anti-bacterial and as such should not harm eukaryotic malaria parasites.  
353 Still, neutrophils can generate a potent oxidative burst where cytotoxic reactive oxygen  
354 species (ROS) are released into phagosomes and their close vicinity. To determine whether  
355 neutrophils use ROS to kill iRBC, we tested the capacity of freshly isolated neutrophils to  
356 kill blood stage parasites in the presence or absence of catalase (to eliminate neutrophil  
357 generated H<sub>2</sub>O<sub>2</sub>). We found that under these conditions, neutrophils eliminated >25% of  
358 parasites (**Fig. 2G**) and reduced overall parasitemia (**Fig. 2H**). However, catalase  
359 dramatically reduced neutrophil cytotoxicity (**Fig. 2G**) and reversed the effect of  
360 neutrophils on overall parasitemia (**Fig. 2H**). Taken together, these data suggest that  
361 neutrophils have the capacity to kill blood stages *P. falciparum* parasites through  
362 phagocytosis of iRBCs and targeted oxidative burst. Consequently, we propose that

363 neutrophils may play an important protective role in the management of infection by killing  
364 the malaria parasite and reducing overall parasitemia.

365

### 366 **Neutrophils recognize and target iRBC via PfEMP1**

367 PfEMP1 is the major surface antigen expressed on the surface of iRBCs at the second half  
368 of the parasites life cycle within red blood cells (9). The observation that in the absence of  
369 PfEMP1 expression, neutrophils do not reduce parasitemia (**Fig. 2D-E**) makes it a prime  
370 candidate as a recognition ligand. To validate that PfEMP1 is indeed recognized by  
371 neutrophils, we generated GFP expressing DC-J parasites (see methods), providing us with  
372 a platform for evaluating their interaction with neutrophils by flow cytometry as described  
373 above. Neutrophils were incubated with this parasite line in the presence (control) or  
374 absence (blasticidin-selected) of PfEMP1 expression and the proportion of GFP<sup>+</sup>-  
375 neutrophils was evaluated. We found that the proportion of GFP<sup>+</sup>-neutrophils was  
376 significantly lower when incubated with PfEMP1 deficient iRBCs compared with those  
377 incubated with control iRBCs (**Fig. 3A**) implying that neutrophil interaction with iRBCs is  
378 largely PfEMP1-mediated. To further validate this observation, we trypsin treated iRBCs  
379 to remove all surface proteins including PfEMP1s. Trypsin-treated DC-J (wild type i.e.  
380 expressing PfEMP1) and trypsin-treated PfEMP1 deficient KO parasites showed similar  
381 interaction with neutrophils (**Fig. 3B**) pointing to PfEMP1 as the main surface protein  
382 recognized by neutrophils. To further investigate the importance of PfEMP1 in the  
383 neutrophil mediated killing of iRBCs, we generated a luciferase expressing DC-J line.  
384 When co-cultured with neutrophils, elimination of PfEMP1-deficient parasites was

385 significantly reduced compared with control PfEMP1 expressing parasites (**Fig. 3C**),  
386 further supporting PfEMP1 as a major recognition ligand of neutrophils.

387

### 388 **Neutrophils ICAM-1 is essential for iRBCs elimination**

389 The reduced interaction between PfEMP1 deficient iRBCs and neutrophils points  
390 to the importance of this family of variant surface antigens. PfEMP1 molecules are known  
391 to interact with various endothelial host receptors including ICAM-1 and EPCR (4, 7, 8)  
392 that are also abundantly expressed on neutrophils (36, 37). Thus, we hypothesized that  
393 these receptors might play a role in mediating interaction between neutrophils and iRBCs.  
394 The short life span of human neutrophils precludes their genetic manipulation. Therefore,  
395 to substantiate this hypothesis we used the neutrophil-like PLB985 cell line transduced  
396 with ICAM-1 or EPCR specific shRNAs. As a result, reduced expression of ICAM-1 was  
397 accompanied with an increase in EPCR mRNA levels (**Fig. 4A**), and knocking down EPCR  
398 led to approximately 7-fold increase in ICAM-1 expression (**Fig. 4B**), suggesting a possible  
399 compensatory mechanism between the two receptors. Using flow cytometry analysis, we  
400 confirmed that while ICAM knock-down reduced its expression on the cell surface, EPCR  
401 knock-down resulted in surface over-expression of ICAM-1 (**Fig. 4C**). We then tested how  
402 knocking down the expression of ICAM-1 or EPCR in neutrophils affects their interaction  
403 with iRBCs harboring GFP<sup>+</sup> parasites. We found that the fraction of GFP<sup>+</sup>-neutrophils was  
404 significantly reduced in the ICAM-1kd cells compared with those infected with the non-  
405 targeting (control) shRNA (**Fig. 4D**). In contrast, the EPCRkd cells, in which ICAM-1 was  
406 overexpressed, showed increased neutrophil-iRBC interaction (**Fig. 4D**).

407 We next used two complementary strategies to conclusively determine if interfering  
408 with PfEMP1-ICAM-1 interaction reduces neutrophil-iRBC contact and iRBC elimination.  
409 First, we show that a monoclonal antibody targeting the PfEMP1-binding domain of  
410 ICAM-1 (28) significantly reduced the ability of neutrophils to kill blood stage parasites  
411 (**Fig. 4E**). Importantly, an ICAM-1 antibody targeting a different domain in ICAM-1 that  
412 does not block ICAM-1-PfEMP1 interaction had no significant effect (**Fig. 4E**). In  
413 addition, we show that the ICAM-1 antibody that blocks ICAM-1-PfEMP1 interaction  
414 significantly inhibits neutrophil-iRBC interaction (**Fig. 4F**). As a second approach, we used  
415 a soluble form of ICAM-1 (fused to a mutated Fc receptor) to compete with the binding of  
416 PfEMP1 to neutrophil expressed ICAM-1. Specifically, NF54-*luc* infected iRBC were  
417 incubated for 6h with naïve human neutrophils in the presence or absence of soluble  
418 ICAM-1-Fc (sICAM-1). We show that incubation with sICAM-1 significantly reduced the  
419 neutrophils' ability to kill parasites (**Fig. 4G**). Altogether, these results highlight ICAM-1  
420 and PfEMP1 as the main mediators of neutrophil interaction with iRBCs, ultimately  
421 leading to the killing of *P. falciparum*.

422

### 423 **Neutrophils impose strong selective pressure against ICAM-1 binding iRBCs** 424 **expressing PfEMP1 implicated in cerebral malaria**

425 Different PfEMP1 variants were shown to bind different endothelial receptors. Our data,  
426 pointing that neutrophil ICAM-1 interaction with PfEMP1 is required for parasite  
427 elimination led us to hypothesize that neutrophils may selectively eliminate parasite  
428 populations that express a subset of PfEMP1 with ICAM-1 cytoadhesive properties. To test  
429 this hypothesis, we set to determine whether neutrophils would preferentially kill parasites

430 expressing ICAM-1 binding PfEMP1. We used NF54 parasites which were pre-selected to  
431 express ICAM-1-binding PfEMP1 that was implicated in cerebral malaria (48). This  
432 selection yields isolation of a relatively homogenous parasite population that primarily  
433 transcribe a single *var* gene (PFD1235w/ PF3D7\_0425800) expressing ICAM-1 binding  
434 PfEMP1 on the iRBC surface (**Fig. 5A**). This line was transfected with luciferase-reporter  
435 plasmid to allow performing killing assays as described above. We found that the ability  
436 of neutrophils to kill parasites was significantly higher in the ICAM-1 selected parasite line  
437 compared with unselected control line expressing other *var* genes (**Fig. 5B**). Similarly, we  
438 found that iRBCs primarily expressing ICAM-1 binding PfEMP1 interact with neutrophils  
439 at a significantly higher rate than iRBCs which were not selected to express ICAM-1  
440 binding PfEMP1 (**Fig 5C**). The differences in interaction and killing were also reflected in  
441 the differences in parasitemia of the two parasite populations which were incubated with  
442 neutrophils and cultured for 5 additional days (**Fig. 5D**). These data indicate that  
443 neutrophils are more efficient in killing parasites that primarily express ICAM-1 binding  
444 PfEMP1. In order to demonstrate how this selection affects antigenic expression among a  
445 parasite population, we evaluated the expression of the entire *var* gene family in ICAM-1  
446 selected parasites with or without neutrophil challenge. We show that in the parasite  
447 population not challenged with neutrophils, the *var* gene encoding for ICAM-1 binding  
448 PfEMP1 (PFD1235w/ PF3D7\_0425800) remained the dominant *var* gene transcript in the  
449 population. However, this transcript is almost undetectable in the parasite population which  
450 was challenged with neutrophils (**Fig. 5E**). Taken together these data suggest that  
451 neutrophils impose strong selective pressure on parasites expressing ICAM-1 binding  
452 PfEMP1.

## 453 Discussion

454 In recent years, mounting evidence implicated components of the innate arm of the  
455 human immune system in important defense mechanisms against malaria infections. For  
456 example, NK cells were shown to produce pro-inflammatory cytokines in malaria infection  
457 and kill iRBCs either directly or via antibody-dependent cell-mediated cytotoxicity  
458 (ADCC) (12). Similarly, monocytes and macrophages play a role in the anti-malaria  
459 immune response via secretion of cytokines and elimination of iRBCs through cytokine  
460 secretion or ADCC. In addition, these cells are large enough and can eliminate iRBCs via  
461 phagocytosis (13). Surprisingly, although neutrophils are the most abundant leukocyte in  
462 human circulation and have well characterized roles in eliminating pathogenic infections,  
463 little is known about their role in malaria (38). The capacity of neutrophils to phagocytose  
464 merozoites and gametocytes *in vitro* was demonstrated years ago (18, 19). In addition,  
465 neutrophils were shown to respond to malaria parasites by generating reactive oxygen  
466 species (39) and by limiting the growth of malaria parasites *in vitro* (20). Recently, it was  
467 shown that neutrophils accumulate in the intervillous space in the placenta during  
468 pregnancy associated malaria (40). However, the mechanisms by which neutrophils  
469 interact and eliminate intracellular blood stage parasites were thus far not elucidated.

470 Here we showed that neutrophils recognize *P. falciparum* iRBC via interaction  
471 between ICAM-1 and PfEMP1, the main antigen expressed by these parasites on the  
472 erythrocyte surface. Once neutrophils and iRBCs interact, the neutrophils are able to clear  
473 approximately 30% of the parasites in culture within less than two hours.

474 *P. falciparum* have the capacity to alternate between the expression of PfEMP1  
475 variants that bind different receptors. The identification of neutrophil ICAM-1 as the iRBC

476 recognition receptor prompted the possibility that neutrophils may exhibit improved killing  
477 efficiency against specific parasite subpopulations that express ICAM-1 binding PfEMP1  
478 variants. Indeed, we demonstrated that neutrophils preferentially interact and clear  
479 parasites expressing ICAM-1 binding PfEMP1. Importantly, we used parasites that were  
480 selected to express PFD1235w/ PF3D7\_0425800, a PfEMP1 variant that was classified as  
481 a group A subtype that facilitates dual binding to human endothelial ICAM-1 as well as to  
482 EPCR (41). The specific affinity to these receptors, expressed primarily by endothelial  
483 cells in brain vasculature, had associated parasites expressing group A PfEMP1 with iRBC  
484 sequestration in brain vasculature and the severe outcome of cerebral malaria (42, 43). In  
485 addition, parasites expressing group A ICAM-1-binding PfEMP1 were shown to induce  
486 cell swelling and damage to the blood barrier thereby contributing to the pathogenesis of  
487 cerebral malaria (38). The strong selective pressure imposed by neutrophils against these  
488 particular parasite populations suggests that they play an important protective role as the  
489 first line of defense against cerebral malaria.

490 Our findings, using naïve neutrophils in culture, correspond with a previous report,  
491 suggesting that even though TNF $\alpha$  stimulation enhances neutrophils' ability to kill blood  
492 stages parasites, it is not obligatory (16). Moreover, careful examination of the data in this  
493 study indicates that even though human neutrophil elimination of *P. falciparum* is  
494 enhanced by TNF $\alpha$  stimulation, neutrophils have a significant capacity to eliminate blood  
495 stage parasites even without any further stimulation. Interestingly, similar clearance rates  
496 were obtained in opsonized and non-opsonized parasites suggesting that the rate limiting  
497 step for iRBCs elimination is the recognition by neutrophils rather than the killing *per se*.  
498 This clearance indeed translated into a significant decrease in the growth rate of the

499 cultured parasite. Clearly, neutrophils' ability to kill intraerythrocytic stages is not  
500 sufficient to completely clear the infection. However, such a significant reduction in  
501 parasitemia *in vivo* may provide an opportunity for additional components of the immune  
502 system to contain the infection.

503 Our observations provide novel insight into the role played by neutrophils in malaria  
504 infection. We demonstrate that neutrophils use both phagocytosis and ROS production to  
505 kill blood stage parasites. Still, the choice of particular killing mechanisms and the possible  
506 involvement of NETosis needs further investigation. Interestingly, the interaction between  
507 neutrophils and iRBCs, involving PfEMP1 and ICAM-1, parallels the interaction between  
508 iRBCs and the endothelium (**Fig. 6**). It is well documented that cytoadhesion triggers local  
509 inflammation (44, 45), and it is therefore plausible that neutrophil interaction with iRBCs  
510 occurs not only in the circulation but also at the site of iRBCs sequestration. The fact that  
511 the same receptor employed by *P. falciparum* to both cytoadhere and avoid removal by the  
512 spleen is also utilized by anti-malarial neutrophils to eliminate the future generation of  
513 parasites inside iRBCs, may represent another aspect of host-pathogen co-evolution.

514 As it appears, not all neutrophils actively engage in iRBC interaction (see **Fig. 1C**)  
515 suggesting the possible existence of different neutrophil subtypes, with different roles in  
516 malaria infection. The concept that neutrophils are not a homogenous population of cells  
517 but actually consist of specialized subsets has been demonstrated in various clinical  
518 conditions ranging from cancer (46) to periodontal disease (47). Our results are in  
519 agreement with these findings and suggest that neutrophil functional heterogeneity may  
520 also be relevant in response to other infectious pathogens.



521        Apparently, PfEMP1 is not the only surface protein expressed by the parasite that  
522        mediates neutrophil interaction with iRBCs as demonstrated by the additional reduction  
523        after proteolytic elimination of erythrocyte surface proteins. Additional surface proteins  
524        encoded by multi copy gene families known as *rif stevor* and *Pf-2TM* were implicated in  
525        immune evasion and malaria pathogenicity (2, 48-55). Neutrophil's ICAM-1, like PfEMP1,  
526        is not solely responsible for mediating the neutrophil-iRBC interaction as knocking down  
527        ICAM-1 expression did not completely abolish this interaction. This is also indicated by  
528        the fact that iRBCs opsonization increased their interactions with neutrophils.

529        Neutrophils express a large number of cell surface receptors for pathogen and  
530        inflammatory environment sensing. These include G-protein-coupled receptors, Fc-  
531        receptors, adhesion receptors such as selectins and integrins, various cytokine receptors  
532        and innate immune receptors such as Toll-like receptors and C-type lectins (56). Among  
533        others, neutrophils express both ICAM-1 and EPCR, which are known ligands for PfEMP1,  
534        the main virulence factor of *P. falciparum* parasites. While the role of other neutrophil  
535        receptors for iRBC recognition is not clear, our data demonstrates the importance of  
536        neutrophil ICAM-1 for their interaction and clearance of iRBC. Further detailed  
537        investigation of the interactions between neutrophils and other parasite surface ligands is  
538        required to comprehensively understand how neutrophils function in malaria infection.

539

540

541 **Acknowledgments**

542 ZG is supported by Israel Science Foundation (ISF) Grant 405/18, the Israel Cancer  
543 Research Fund, the Deutsche Forschungsgemeinschaft (DFG) and the Rosetrees Trust. ZG  
544 is also supported by the Samuel and Isabel Friedman Chair in Experimental Medicine. This  
545 work was supported partially by the Israeli Academy for Science, Israel Science  
546 Foundation (ISF) Grant 1523/18 and in part by European Research Council (erc.europa.eu)  
547 Consolidator Grant 615412 (to R.D.). RD is also supported by the Dr. Louis M. Leland and  
548 Ruth M. Leland Chair in Infectious Diseases. ARJ is supported by the Lundbeck  
549 Foundation (R313-2019-322). The Danish Agency for Higher Education and Science  
550 International Network Programme supported the collaboration between ARJ and RD  
551 (0192-00058B). We are thankful to Dr. Borko Amulic for kindly providing us with the  
552 human myeloid leukemia PLB-985 cell line.

553

554 **Figure legends:**

555

556 **Figure 1. Human neutrophils interact with and phagocytose *Plasmodium falciparum*-**  
557 **infected red blood cells.**

558 **(A).** Human neutrophils stained for CD66b after incubation with RBCs infected with GFP<sup>+</sup>  
559 *P. falciparum* parasites (white arrows). Nuclei were stained with DAPI (blue), Neutrophils  
560 stained against CD66b are shown in red, GFP labeled parasites are shown in green. Scale  
561 bar, 5 μm. The upper and lower panel are two different cells. **(B).** Giemsa staining of  
562 freshly isolated human neutrophils from a healthy donor incubated with iRBCs harboring  
563 late stages *P. falciparum* parasites (black arrows). Scale bar 10 μm. **(C).** Flow cytometry  
564 analysis of human neutrophils incubated with opsonized or non-opsonized GFP<sup>+</sup> late-  
565 staged iRBCs. **(D).** Quantification of GFP<sup>+</sup> iRBCs phagocytosed by neutrophils measured  
566 by flow cytometry. Results represent the average of 3 biological replicates ± standard error  
567 of the mean. (\* = p<0.05).

568

569 **Figure 2. Human neutrophils eliminate *P. falciparum* parasites in culture.**

570 **(A).** “Pulse-Chase” experiment measuring the interactions between neutrophils and  
571 opsonized (red) or non-opsonized (blue) GFP<sup>+</sup> iRBC over time (percentage of GFP<sup>+</sup>  
572 neutrophils at 5 minutes defined as 100%) measured by flow cytometry. **(B).** Proposed  
573 model - the reduction in GFP<sup>+</sup> neutrophils may be explained by the escape of GFP<sup>+</sup> iRBCs  
574 (upper) which will not affect parasite propagation in culture or by elimination of GFP<sup>+</sup>  
575 iRBCs (lower, either extracellularly or following phagocytosis) which will impair parasite  
576 propagation in culture. **(C).** Expansion of NF54 iRBC cultured alone or supplemented daily

577 with freshly isolated neutrophils. **(D)**. The percentage of parasitemia of several *P.*  
578 *falciparum* isolates (NF54; Dd2; SL and PfEMP1ko) cultured in the presence (Neut.) or  
579 absence (Cont.) of neutrophils. **(E)**. The fold reduction in iRBC following neutrophil  
580 challenge. **(F)**. Flow cytometric analysis of the effect of neutrophil challenge on parasite  
581 cell cycle progression. **(G)**. Short term neutrophil killing of late-stage NF54-luc in the  
582 presence (red) or absence (blue) of catalase. **(H)**, The effect of neutrophil challenge on  
583 culture parasitemia in the presence or absence of catalase. Results represents the average  
584 of 3 biological replicates  $\pm$  standard error. (\* =  $p < 0.05$ , \*\* =  $p < 0.01$ ).

585

586 **Figure 3. PfEMP1 is a major ligand mediating the interaction and killing of iRBCs**  
587 **by human neutrophils.**

588 **(A)**. Representative flow cytometric analysis of human neutrophils cultured alone  
589 (Control), with late stage wild type (wild type) or PfEMP1ko (PfEMP1ko) GFP<sup>+</sup> iRBC.

590 **(B)**. Flow cytometric quantification of the effect of trypsin treatment on neutrophil  
591 interaction with wild type and PfEMP1ko GFP<sup>+</sup> iRBC. **(C)**. Luciferase-based killing assay  
592 demonstrating the extent of neutrophil elimination of late stage wild type (wt) and  
593 PfEMP1ko iRBC. Results represent the average of 3 biological replicates  $\pm$  standard error.

594 (\* =  $p < 0.05$ , \*\* =  $p < 0.01$ ).

595

596 **Figure 4. Neutrophil ICAM-1 is an essential receptor for their killing ability of iRBCs.**

597 **(A-B)**. qRT-PCR analysis of the relative expression of ICAM-1 and EPCR in control,  
598 ICAM-1kd and EPCRkd PLB985 cells. **(C)**. Flow cytometric analysis of surface ICAM-1  
599 expression in control, ICAM-1kd and EPCRkd PLB985 cells. **(D)**. Flow cytometry

600 quantification of GFP<sup>+</sup> iRBC with control, ICAM-1kd and EPCRkd PLB985 cells. **(E)**.  
601 Short term killing assay of NF54-luc parasites incubated with neutrophils in the presence  
602 of CD11b and ICAM-1 blocking and non-blocking antibodies. **(F)**. % reduction in GFP<sup>+</sup>  
603 iRBC interaction with neutrophil in the presence of CD11b and ICAM-1 blocking  
604 antibodies and quantified by flow cytometry. **(G)**. Short term neutrophil killing of NF54-  
605 *luc* in the presence or absence of soluble ICAM-1-Fc fusion protein (sICAM-1-Fc). Results  
606 represent the average of 3 biological replicates  $\pm$  standard error. (\*\* =  $p < 0.01$ ).

607

608 **Figure 5. Neutrophils strongly select against ICAM-1-binding PfEMP1.**

609 **(A)**. I. Steady state mRNA levels of the entire *var* gene family measured by qRT-PCR from  
610 ICAM-1 selected line transfected with luciferase expression vector demonstrating that  
611 PFD1235w/PF3D7\_0425800 is the transcriptionally dominant *var* gene. II. Immuno-  
612 fluorescence imaging using anti-ICAM-1-binding-PfEMP1 antibody demonstrating its  
613 expression on the surface of the iRBC. **(B)**. Short term neutrophil killing of unselected  
614 NF54 and PFD1235w selected lines. **(C)**. Flow cytometric quantification of neutrophil  
615 interaction with MitoTracker (APC<sup>+</sup>) stained NF54 iRBC and PFD1235w iRBC selected  
616 lines. **(D)**. Percent reduction in parasitemia of NF54 and PFD1235w selected parasites after  
617 5 days of co-culture with neutrophils, compared to unchallenged parasites **(E)**. *var* gene  
618 transcription profiles measured by qRT-PCR of PFD1235w-selected parasite line cultured  
619 in the absence (upper panel) or presence (lower panel) of neutrophils. Steady state mRNA  
620 levels of each individual *var* gene are presented as relative copy number to the  
621 housekeeping gene arginyl-tRNA synthetase (PFL0900c). Results represent the average of  
622 3 biological replicates  $\pm$  standard error. (\*\* =  $p < 0.01$ ).

623

624 **Figure 6. Graphic abstract**

625 iRBCs adhere to the endothelium as a strategy for escaping immune elimination (left). The  
626 interaction between iRBC is mediated by PfEMP1 and endothelial ICAM-  
627 1/CSA/CD36/EPCR (left). ICAM-1 expressed on the neutrophil surface interacts with  
628 PfEMP1 and leads to parasite elimination (right).

629

630

631 References

- 632 1. WHO (2016) World Malaria Report, 2016.186.
- 633 2. Dzikowski R, Templeton TJ, & Deitsch K (2006) Variant antigen gene expression  
634 in malaria. *Cell Microbiol* 8(9):1371-1381.
- 635 3. Baruch DI, et al. (1995) Cloning the *P. falciparum* gene encoding PfEMP1, a  
636 malarial variant antigen and adherence receptor on the surface of parasitized human  
637 erythrocytes. *Cell* 82:77-87.
- 638 4. Bengtsson A, et al. (2013) A novel domain cassette identifies *Plasmodium*  
639 *falciparum* PfEMP1 proteins binding ICAM-1 and is a target of cross-reactive,  
640 adhesion-inhibitory antibodies. *J Immunol* 190(1):240-249.
- 641 5. Smith JD, Gamain B, Baruch DI, & Kyes S (2001) Decoding the language of var  
642 genes and *Plasmodium falciparum* sequestration. *Trends Parasitol.* 17(11):538-545.
- 643 6. Janes JH, et al. (2011) Investigating the Host Binding Signature on the *Plasmodium*  
644 *falciparum* PfEMP1 Protein Family. *PLoS Pathog* 7(5):e1002032.
- 645 7. Turner L, et al. (2013) Severe malaria is associated with parasite binding to  
646 endothelial protein C receptor. *Nature* 498(7455):502-505.
- 647 8. Smith JD, Rowe JA, Higgins MK, & Lavstsen T (2013) Malaria's deadly grip:  
648 cytoadhesion of *Plasmodium falciparum*-infected erythrocytes. *Cell Microbiol*  
649 15(12):1976-1983.
- 650 9. Pasternak ND & Dzikowski R (2008) PfEMP1: An antigen that plays a key role in  
651 the pathogenicity and immune evasion of the malaria parasite *Plasmodium*  
652 *falciparum*. *Int J Biochem Cell Biol.*

- 653 10. Deitsch KW & Dzikowski R (2017) Variant Gene Expression and Antigenic  
654 Variation by Malaria Parasites. *Annu Rev Microbiol*.
- 655 11. Miller LH, Baruch DI, Marsh K, & Doumbo OK (2002) The pathogenic basis of  
656 malaria. *Nature* 415(6872):673-679.
- 657 12. Wolf AS, Sherratt S, & Riley EM (2017) NK Cells: Uncertain Allies against  
658 Malaria. *Front Immunol* 8:212.
- 659 13. Chua CL, Brown G, Hamilton JA, Rogerson S, & Boeuf P (2013) Monocytes and  
660 macrophages in malaria: protection or pathology? *Trends Parasitol* 29(1):26-34.
- 661 14. Amulic B & Hayes G (2011) Neutrophil extracellular traps. *Curr Biol* 21(9):R297-  
662 298.
- 663 15. Amulic B, Cazalet C, Hayes GL, Metzler KD, & Zychlinsky A (2012) Neutrophil  
664 function: from mechanisms to disease. *Annual review of immunology* 30:459-489.
- 665 16. Kumaratilake LM, Ferrante A, & Rzepczyk CM (1990) Tumor necrosis factor  
666 enhances neutrophil-mediated killing of *Plasmodium falciparum*. *Infect Immun*  
667 58(3):788-793.
- 668 17. Olivier M, Van Den Ham K, Shio MT, Kassa FA, & Fougeray S (2014) Malarial  
669 pigment hemozoin and the innate inflammatory response. *Front Immunol* 5:25.
- 670 18. Trubowitz S & Masek B (1968) *Plasmodium falciparum*: phagocytosis by  
671 polymorphonuclear leukocytes. *Science* 162(3850):273-274.
- 672 19. Sinden RE & Smalley ME (1976) Gametocytes of *Plasmodium falciparum*:  
673 phagocytosis by leucocytes in vivo and in vitro. *Trans R Soc Trop Med Hyg*  
674 70(4):344-345.







- 675 20. Brown J & Smalley ME (1981) Inhibition of the in vitro growth of Plasmodium  
676 falciparum by human polymorphonuclear neutrophil leucocytes. Clin Exp Immunol  
677 46(1):106-109.
- 678 21. Stijlemans B, et al. (2015) Development of a pHrodo-based assay for the  
679 assessment of in vitro and in vivo erythrophagocytosis during experimental  
680 trypanosomosis. PLoS neglected tropical diseases 9(3):e0003561.
- 681 22. Dzikowski R, Frank M, & Deitsch K (2006) Mutually exclusive expression of  
682 virulence genes by malaria parasites is regulated independently of antigen  
683 production. PLoS Pathog 2(3):e22.
- 684 23. Epp C, Raskolnikov D, & Deitsch KW (2008) A regulatable transgene expression  
685 system for cultured Plasmodium falciparum parasites. Malar J 7:86.
- 686 24. Wu Y, Sifri CD, Lei HH, Su XZ, & Wellems TE (1995) Transfection of  
687 Plasmodium falciparum within human red blood cells. Proc Natl Acad Sci U S A  
688 92(4):973-977.
- 689 25. Deitsch KW, Driskill CL, & Wellems TE (2001) Transformation of malaria  
690 parasites by the spontaneous uptake and expression of DNA from human  
691 erythrocytes. Nucleic Acids Research 29(3):850-853.
- 692 26. Amit-Avraham I, et al. (2015) Antisense long noncoding RNAs regulate var gene  
693 activation in the malaria parasite Plasmodium falciparum. Proc Natl Acad Sci U S  
694 A 112(9):E982-991.
- 695 27. Sagiv JY, Voels S, & Granot Z (2016) Isolation and Characterization of Low- vs.  
696 High-Density Neutrophils in Cancer. Methods Mol Biol 1458:179-193.

- 697 28. Baratin M, et al. (2007) Dissection of the role of PfEMP1 and ICAM-1 in the  
698 sensing of Plasmodium-falciparum-infected erythrocytes by natural killer cells.  
699 PLoS One 2(2):e228.
- 700 29. Fastman Y, et al. (2018) An upstream open reading frame (uORF) signals for  
701 cellular localization of the virulence factor implicated in pregnancy associated  
702 malaria. Nucleic Acids Res 46(10):4919-4932.
- 703 30. Kyes S, Pinches R, & Newbold C (2000) A simple RNA analysis method shows  
704 var and rif multigene family expression patterns in Plasmodium falciparum.  
705 Mol.Biochem.Parasitol. 105(2):311-315.
- 706 31. Salanti A, et al. (2003) Selective upregulation of a single distinctly structured var  
707 gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in  
708 pregnancy-associated malaria. Mol Microbiol 49(1):179-191.
- 709 32. Frank M, Dzikowski R, Amulic B, & Deitsch K (2007) Variable switching rates of  
710 malaria virulence genes are associated with chromosomal position. Mol Microbiol  
711 64(6):1486-1498.
- 712 33. Stanietsky N, et al. (2009) The interaction of TIGIT with PVR and PVRL2 inhibits  
713 human NK cell cytotoxicity. Proc Natl Acad Sci U S A 106(42):17858-17863.
- 714 34. Dahan-Pasternak N, et al. (2013) PfSec13 is an unusual chromatin associated  
715 nucleoporin of Plasmodium falciparum, which is essential for parasite proliferation  
716 in human erythrocytes. J Cell Sci.
- 717 35. Kolevzon N, Nasereddin A, Naik S, Yavin E, & Dzikowski R (2014) Use of peptide  
718 nucleic acids to manipulate gene expression in the malaria parasite Plasmodium  
719 falciparum. PLoS One 9(1):e86802.

- 720 36. Wang JH, et al. (1997) Intercellular adhesion molecule-1 (ICAM-1) is expressed  
721 on human neutrophils and is essential for neutrophil adherence and aggregation.  
722 Shock 8(5):357-361.
- 723 37. Sturn DH, et al. (2003) Expression and function of the endothelial protein C  
724 receptor in human neutrophils. Blood 102(4):1499-1505.
- 725 38. Ley K, et al. (2018) Neutrophils: New insights and open questions. Sci Immunol  
726 3(30).
- 727 39. Salmon D, Vilde JL, Andrieu B, Simonovic R, & Lebras J (1986) Role of immune  
728 serum and complement in stimulation of the metabolic burst of human neutrophils  
729 by Plasmodium falciparum. Infect Immun 51(3):801-806.
- 730 40. Bostrom S, et al. (2017) Neutrophil alterations in pregnancy-associated malaria and  
731 induction of neutrophil chemotaxis by Plasmodium falciparum. Parasite Immunol  
732 39(6).
- 733 41. Lennartz F, et al. (2017) Structure-Guided Identification of a Family of Dual  
734 Receptor-Binding PfEMP1 that Is Associated with Cerebral Malaria. Cell Host  
735 Microbe 21(3):403-414.
- 736 42. Tuikue Ndam N, et al. (2017) Parasites Causing Cerebral Falciparum Malaria Bind  
737 Multiple Endothelial Receptors and Express EPCR and ICAM-1-Binding PfEMP1.  
738 J Infect Dis 215(12):1918-1925.
- 739 43. Jensen AR, Adams Y, & Hviid L (2020) Cerebral Plasmodium falciparum malaria:  
740 The role of PfEMP1 in its pathogenesis and immunity, and PfEMP1-based vaccines  
741 to prevent it. Immunol Rev 293(1):230-252.

- 742 44. Schofield L (2007) Intravascular infiltrates and organ-specific inflammation in  
743 malaria pathogenesis. *Immunol Cell Biol* 85(2):130-137.
- 744 45. van der Heyde HC, Nolan J, Combes V, Gramaglia I, & Grau GE (2006) A unified  
745 hypothesis for the genesis of cerebral malaria: sequestration, inflammation and  
746 hemostasis leading to microcirculatory dysfunction. *Trends Parasitol* 22(11):503-  
747 508.
- 748 46. Sagiv JY, et al. (2015) Phenotypic diversity and plasticity in circulating neutrophil  
749 subpopulations in cancer. *Cell reports* 10(4):562-573.
- 750 47. Fine N, et al. (2016) Distinct Oral Neutrophil Subsets Define Health and  
751 Periodontal Disease States. *Journal of dental research*.
- 752 48. Lavazec C, Sanyal S, & Templeton TJ (2006) Hypervariability within the Rifin,  
753 Stevor, and Pf mc-2TM superfamilies in *Plasmodium falciparum* *Nucleic Acids*  
754 *Research*.
- 755 49. Lavazec C, Sanyal S, & Templeton TJ (2007) Expression switching in the stevor  
756 and Pfmc-2TM superfamilies in *Plasmodium falciparum*. *Mol.Microbiol.*  
757 64(6):1621-1634.
- 758 50. Niang M, Yan Yam X, & Preiser PR (2009) The *Plasmodium falciparum* STEVOR  
759 multigene family mediates antigenic variation of the infected erythrocyte. *PLoS*  
760 *Pathog* 5(2):e1000307.
- 761 51. Niang M, et al. (2014) STEVOR is a *Plasmodium falciparum* erythrocyte binding  
762 protein that mediates merozoite invasion and rosetting. *Cell Host Microbe*  
763 16(1):81-93.

- 764 52. Kyes SA, Rowe JA, Kriek N, & Newbold CI (1999) Rifins: a second family of  
765 clonally variant proteins expressed on the surface of red cells infected with  
766 *Plasmodium falciparum*. *Proc.Natl.Acad.Sci.U.S.A* 96(16):9333-9338.
- 767 53. Bachmann A, et al. (2015) A comparative study of the localization and membrane  
768 topology of members of the RIFIN, STEVOR and PfMC-2TM protein families in  
769 *Plasmodium falciparum*-infected erythrocytes. *Malar J* 14:274.
- 770 54. Saito F, et al. (2017) Immune evasion of *Plasmodium falciparum* by RIFIN via  
771 inhibitory receptors. *Nature* 552(7683):101-105.
- 772 55. Ch'ng JH, et al. (2017) Epitopes of anti-RIFIN antibodies and characterization of  
773 rif-expressing *Plasmodium falciparum* parasites by RNA sequencing. *Scientific*  
774 *reports* 7:43190.
- 775 56. Futosi K, Fodor S, & Mocsai A (2013) Reprint of Neutrophil cell surface receptors  
776 and their intracellular signal transduction pathways. *Int Immunopharmacol*  
777 17(4):1185-1197.
- 778

**A.****B.****C.****D.****Figure 1**




Figure 2





Figure 3











Figure 4

**A.****B.****C.****D.****E.****Figure 5**




Figure 6